$Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients$

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Show other versions (1)

CorrigendumNielsen SA, McDonald MB, Majmudar PA. Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients. Clinical Ophthalmology. 2013;7:149–156. The paper titled "Safety of besifloxacin ophthalmic suspension 0.6% in...

Full description

Bibliographic Details
Main Authors:	Nielsen SA, McDonald MB, Majmudar PA
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-04-01
Series:	Clinical Ophthalmology
Online Access:	http://www.dovepress.com/opth-38279-safety-of-besifloxacin-ophthalmic-suspensicorrigendum-a12756

Similar Items

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
by: Nielsen SA, et al.
Published: (2013-01-01)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
by: Silverstein BE, et al.
Published: (2012-11-01)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
by: Morris TW, et al.
Published: (2011-09-01)

Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens
by: Comstock TL, et al.
Published: (2014-04-01)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
by: Haas W, et al.
Published: (2011-09-01)

Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
by: S. Khimdas, et al.
Published: (2011-01-01)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
by: Heleen H DeCory, et al.
Published: (2020-01-01)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
by: Malhotra R, et al.
Published: (2012-06-01)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
by: Bucci FA Jr, et al.
Published: (2015-05-01)

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
by: Haas W, et al.
Published: (2013-05-01)

Spectral Analysis and Structural Elucidation of Besifloxacin Hydrochloride
by: ZHANG Ming-guang, et al.
Published: (2018-09-01)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
by: Khaimi MA
Published: (2018-02-01)

Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis
by: Jun-Jie Wang, et al.
Published: (2019-12-01)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
by: Timothy L Comstock, et al.
Published: (2010-03-01)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
by: Wang XJ, et al.
Published: (2011-10-01)

Assessment of refractive outcome of femtosecond-assisted LASIK for hyperopia correction
by: Mohamed Tarek El-Naggar,, et al.
Published: (2017-03-01)

Regressão refrativa total pós-LASIK: relato de caso Total refractive regression post-LASIK: case report
by: Patrícia Ioschpe Gus, et al.
Published: (2005-06-01)

LASIK-LASEK en defectos refractivos poscirugías de catarata LASIK-LASEK in refractive defects after cataract surgeries
by: Juan Raúl Hernández Silva, et al.
Published: (2008-12-01)

Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
by: John D. Sheppard, et al.
Published: (2019-02-01)

Evaluations of refraction competencies of ophthalmic technicians in Mozambique
by: Kajal Shah, et al.
Published: (2016-07-01)

LASIK for spherical refractive myopia: effect of topographic astigmatism (ocular residual astigmatism, ORA) on refractive outcome.
by: Andreas Frings, et al.
Published: (2015-01-01)

Predictability and stability of refraction with increasing optical zone diameter in hyperopic LASIK
by: Mostafa A El-Helw, et al.
Published: (2010-05-01)

Evaluation of Refractive Results of LASIK and LASEK in Patients with Myopia and Myopic Astigmatism
by: Okan Taşkın, et al.
Published: (2014-10-01)

Under-the-Flap Crosslinking and LASIK in Early Ectasia with Hyperopic Refractive Error
by: Sylvain el-Khoury, et al.
Published: (2018-01-01)

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
by: Bruce I Gaynes, et al.
Published: (2008-06-01)

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
by: Gail Torkildsen, et al.
Published: (2010-04-01)

Refractive outcomes of an advanced aspherically optimized profile for myopia corrections by LASIK: a retrospective comparison with the standard aspherically optimized profile
by: Meyer B, et al.
Published: (2015-02-01)

Comment on “Under-the-Flap Crosslinking and LASIK in Early Ectasia with Hyperopic Refractive Error”
by: Avi Wallerstein, et al.
Published: (2019-01-01)

Role of percent peripheral tissue ablated on refractive outcomes following hyperopic LASIK.
by: George Fatseas, et al.
Published: (2017-01-01)

Clinical analysis of refractive regression after LASIK in moderate and high myopic eyes
by: Jing Gao, et al.
Published: (2019-04-01)

Corrigendum to “Under-the-Flap Crosslinking and LASIK in Early Ectasia with Hyperopic Refractive Error”
by: Sylvain el-Khoury, et al.
Published: (2019-01-01)

Relative peripheral refraction across 4 meridians after orthokeratology and LASIK surgery
by: António Queirós, et al.
Published: (2018-05-01)

Hyperopic refractive correction by LASIK, SMILE or lenticule reimplantation in a non-human primate model.
by: Geraint P Williams, et al.
Published: (2018-01-01)

Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients
by: Yuri Sakane, et al.
Published: (2019-01-01)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
by: Joseph Blondeau, et al.
Published: (2021-05-01)

Corrigendum to “Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients”
by: Yuri Sakane, et al.
Published: (2020-01-01)

Comparison of refractive outcomes of femtosecond LASIK with two different flap thickness in the correction of myopia
by: Ai-Ping Liao, et al.
Published: (2020-05-01)

Comparison of visual acuity, refractive results and complications of femtosecond laser with mechanical microkeratome in LASIK
by: Murat Moray, et al.
Published: (2013-06-01)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
by: Marlowe ZT, et al.
Published: (2013-12-01)

The ophthalmic health and refractive state of working dogs in South Brazil
by: Juliana Kravetz de Oliveira, et al.
Published: (2020-02-01)